Adipokine actions on cartilage homeostasis

Advances in Clinical Chemistry

Volumn 55, Issue , 2011, Pages 61-79

  Dozio, Elena ^a   Corsi, Massimiliano M ^a,b   Ruscica, Massimiliano ^c   Passafaro, Luca ^c   Steffani, Liliana ^c   Banfi, Giuseppe ^a,b   Magni, Paolo ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

Author keywords

Adipokines; Cartilage homeostasis; Leptin receptors; Proinflammatory cytokines; Synovial fluid

Indexed keywords

EID: 80052690009     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-387042-1.00004-6     Document Type: Chapter

References (78)

1. Anderson J.J., Felson D.T. Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey (HANES I). Evidence for an association with overweight, race, and physical demands of work. Am. J. Epidemiol. 1988, 128:179-189.
2. Cicuttini F.M., Baker J.R., Spector T.D. The association of obesity with osteoarthritis of the hand and knee in women: a twin study. J. Rheumatol. 1996, 23:1221-1226.
3. Mohamed-Ali V., Pinkney J.H., Coppack S.W. Adipose tissue as an endocrine and paracrine organ. Int. J. Obes. Relat. Metab. Disord. 1998, 22:1145-1158.
4. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
5. Scherer P.E. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006, 55:1537-1545.
6. Rosen C.J., Bouxsein M.L. Mechanisms of disease: is osteoporosis the obesity of bone?. Nat. Clin. Pract. Rheumatol. 2006, 2:35-43.
7. Lee N.K., Sowa H., Hinoi E., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130:456-469.
8. Magni P., Dozio E., Galliera E., Ruscica M., Corsi M.M. Molecular aspects of adipokine-bone interactions. Curr. Mol. Med. 2010, 10:522-532.
9. Ku J.H., Lee C.K., Joo B.S., et al. Correlation of synovial fluid leptin concentrations with the severity of osteoarthritis. Clin. Rheumatol. 2009, 28:1431-1435.
10. Simopoulou T., Malizos K.N., Iliopoulos D., et al. Differential expression of leptin and leptin's receptor isoform (Ob-Rb) mRNA between advanced and minimally affected osteoarthritic cartilage; effect on cartilage metabolism. Osteoarthritis Cartilage 2007, 15:872-883.
11. Bao J.P., Chen W.P., Feng J., Hu P.F., Shi Z.L., Wu L.D. Leptin plays a catabolic role on articular cartilage. Mol. Biol. Rep. 2009, Oct 30 [Epub ahead of print].
12. Vuolteenaho K., Koskinen A., Kukkonen M., et al. Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage-mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production. Mediators Inflamm. 2009, 2009:345838.
13. Hao D., Li M., Wu Z., Duan Y., Li D., Qiu G. Synovial fluid level of adiponectin correlated with levels of aggrecan degradation markers in osteoarthritis. Rheumatol. Int. 2010, May 13 [Epub ahead of print].
14. Schaffler A., Ehling A., Neumann E., et al. Adipocytokines in synovial fluid. JAMA 2003, 290:1709-1710.
15. Otero M., Lago R., Gomez R., et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2006, 65:1198-1201.
16. Choi H.M., Lee Y.A., Lee S.H., et al. Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. Arthritis Res. Ther. 2009, 11:R161.
17. Ehling A., Schaffler A., Herfarth H., et al. The potential of adiponectin in driving arthritis. J. Immunol. 2006, 176:4468-4478.
18. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 2006, 6:772-783.
19. Zhang Z., Xing X., Hensley G., et al. Resistin induces expression of proinflammatory cytokines and chemokines in human articular chondrocytes via transcription and messenger RNA stabilization. Arthritis Rheum. 2010, 62:1993-2003.
20. Lee J.H., Ort T., Ma K., et al. Resistin is elevated following traumatic joint injury and causes matrix degradation and release of inflammatory cytokines from articular cartilage in vitro. Osteoarthritis Cartilage 2009, 17:613-620.
21. Bokarewa M., Nagaev I., Dahlberg L., Smith U., Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J. Immunol. 2005, 174:5789-5795.
22. Senolt L., Housa D., Vernerova Z., et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann. Rheum. Dis. 2007, 66:458-463.
23. Moschen A.R., Kaser A., Enrich B., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 2007, 178:1748-1758.
24. Brentano F., Schorr O., Ospelt C., et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum. 2007, 56:2829-2839.
25. Gosset M., Berenbaum F., Salvat C., et al. Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis. Arthritis Rheum. 2008, 58:1399-1409.
26. Hu P.F., Tang J.L., Chen W.P., Bao J.P., Wu L.D. Increased apelin serum levels and expression in human chondrocytes in osteoarthritic patients. Int. Orthop. 2010, Jul 22 [Epub ahead of print].
27. Tartaglia L.A., Demski M., Weng X., et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995, 83:1263-1271.
28. Tartaglia L.A. The leptin receptor. J. Biol. Chem. 1997, 272:6093-6096.
29. Banks A.S., Davis S.M., Bates S.H., Myers M.G. Activation of downstream signals by the long form of the leptin receptor. J. Biol. Chem. 2000, 275:14563-14572.
30. Yang G., Ge H., Boucher A., Yu X., Li C. Modulation of direct leptin signaling by soluble leptin receptor. Mol. Endocrinol. 2004, 18:1354-1362.
31. Rosenbaum M., Murphy E.M., Heymsfield S.B., Matthews D.E., Leibel R.L. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J. Clin. Endocrinol. Metab. 2002, 87:2391-2394.
32. Van Dielen F.M.H., Van't Veer C., Buurman W.A., Greve J.W.M. Leptin and soluble leptin receptor levels in obese and weight-losing individuals. J. Clin. Endocrinol. Metab. 2002, 87:1708-1716.
33. Magni P., Liuzzi A., Ruscica M., et al. Free and bound plasma leptin in normal weight and obese men and women: relationship with body composition, resting energy expenditure, insulin-sensitivity, lipid profile and macronutrient preference. Clin. Endocrinol. 2005, 62:189-196.
34. Teichtahl A.J., Wluka A.E., Proietto J., Cicuttini F.M. Obesity and the female sex, risk factors for knee osteoarthritis that may be attributable to systemic or local leptin biosynthesis and its cellular effects. Med. Hypotheses 2005, 65:312-315.
35. Presle N., Pottie P., Dumond H., et al. Differential distribution of adipokines between serum and synovial fluid in patients with osteoarthritis. Contribution of joint tissues to their articular production. Osteoarthritis Cartilage 2006, 14:690-695.
36. Watkins B.A., Li Y., Seifert M.F. Nutraceutical fatty acids as biochemical and molecular modulators of skeletal biology. J. Am. Coll. Nutr. 2001, 20:410S-416S. discussion 417S-420S.
37. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1595-1599.
38. Tsao T.S., Tomas E., Murrey H.E., et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J. Biol. Chem. 2003, 278:50810-50817.
39. Matsuzawa Y. White adipose tissue and cardiovascular disease. Best Pract. Res. Clin. Endocrinol. Metab. 2005, 19:637-647.
40. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999, 257:79-83.
41. Vilarrasa N., Vendrell J., Maravall J., et al. Distribution and determinants of adiponectin, resistin and ghrelin in a randomly selected healthy population. Clin. Endocrinol. 2005, 63:329-335.
42. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol. 2003, 23:85-89.
43. Yang W.S., Lee W.J., Funahashi T., et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J. Clin. Endocrinol. Metab. 2001, 86:3815-3819.
44. Hug C., Wang J., Ahmad N.S., Bogan J.S., Tsao T.S., Lodish H.F. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc. Natl. Acad. Sci. USA 2004, 101:10308-10313.
45. Neumeier M., Weigert J., Schaffler A., et al. Different effects of adiponectin isoforms in human monocytic cells. J. Leukoc. Biol. 2006, 79:803-808.
46. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001, 7:941-946.
47. Berg A.H., Combs T.P., Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. 2002, 13:84-89.
48. Nawrocki A.R., Scherer P.E. The delicate balance between fat and muscle: adipokines in metabolic disease and musculoskeletal inflammation. Curr. Opin. Pharmacol. 2004, 4:281-289.
49. Lago R., Gomez R., Otero M., et al. A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. Osteoarthritis Cartilage 2008, 16:1101-1109.
50. Chen T.H., Chen L., Hsieh M.S., Chang C.P., Chou D.T., Tsai S.H. Evidence for a protective role for adiponectin in osteoarthritis. Biochim. Biophys. Acta 2006, 1762:711-718.
51. Ebina K., Fukuhara A., Ando W., et al. Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction. Clin. Rheumatol. 2009, 28:445-451.
52. Lewicki M., Kotyla P., Kucharz E. Etanercept increases adiponectin level in woman with rheumatoid arthritis. Clin. Rheumatol. 2008, 27:1337-1338.
53. Nagashima T., Okubo-Fornbacher H., Aoki Y., et al. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis. J. Rheumatol. 2008, 35:936-938.
54. Matsubara M., Katayose S., Maruoka S. Decreased plasma adiponectin concentrations in nondiabetic women with elevated homeostasis model assessment ratios. Eur. J. Endocrinol. 2003, 148:343-350.
55. Matsubara M., Namioka K., Katayose S. Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation. Eur. J. Endocrinol. 2003, 148:657-662.
56. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
57. Patel L., Buckels A.C., Kinghorn I.J., et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem. Biophys. Res. Commun. 2003, 300:472-476.
58. Savage D.B., Sewter C.P., Klenk E.S., et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001, 50:2199-2202.
59. Harsch I.A., Koebnick C., Wallaschofski H., et al. Resistin levels in patients with obstructive sleep apnoea syndrome--the link to subclinical inflammation?. Med. Sci. Monit. 2004, 10:CR510-CR515.
60. Reilly M.P., Lehrke M., Wolfe M.L., Rohatgi A., Lazar M.A., Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932-939.
61. Lehrke M., Reilly M.P., Millington S.C., Iqbal N., Rader D.J., Lazar M.A. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med. 2004, 1:e45.
62. Axelsson J., Witasp A., Carrero J.J., et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am. J. Kidney Dis. 2007, 49:237-244.
63. Varma V., Yao-Borengasser A., Rasouli N., et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J. Clin. Endocrinol. Metab. 2007, 92:666-672.
64. Sommer G., Garten A., Petzold S., et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin. Sci. 2008, 115:13-23.
65. Boucher J., Masri B., Daviaud D., et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005, 146:1764-1771.
66. Daviaud D., Boucher J., Gesta S., et al. TNF-α up-regulates apelin expression in human and mouse adipose tissue. FASEB J. 2006, 20:1528-1530.
67. Heinonen M.V., Purhonen A.K., Miettinen P., et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul. Pept. 2005, 130:7-13.
68. De Mota N., Reaux-Le Goazigo A., El Messari S., et al. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc. Natl. Acad. Sci. USA 2004, 101:10464-10469.
69. Kleinz M.J., Davenport A.P. Emerging roles of apelin in biology and medicine. Pharmacol. Ther. 2005, 107:198-211.
70. Hill M.J., Kumar S., McTernan P.G. Adipokines and the clinical laboratory: what to measure, when and how?. J. Clin. Pathol. 2009, 62:206-211.
71. Biolo G., Agostini F., Simunic B., et al. Positive energy balance is associated with accelerated muscle atrophy and increased erythrocyte glutathione turnover during 5 wk of bed rest. Am. J. Clin. Nutr. 2008, 88:950-958.
72. Magni P., Ruscica M., Dozio E., et al. Plasma adiponectin and leptin concentrations in professional rugby players. J. Biol. Regul. Homeost. Agents 2010, 24:87-91.
73. Sinha M.K., Ohannesian J.P., Heiman M.L., et al. Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J. Clin. Invest. 1996, 98:1277-1282.
74. Norata G.D., Raselli S., Grigore L., et al. Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke 2007, 38:2844-2846.
75. Kotani K., Sakane N., Saiga K., Kurozawa Y. Leptin: adiponectin ratio as an atherosclerotic index in patients with type 2 diabetes: relationship of the index to carotid intima-media thickness. Diabetologia 2005, 48:2684-2686.
76. Gandhi R., Takahashi M., Smith H., Rizek R., Mahomed N.N. The synovial fluid adiponectin-leptin ratio predicts pain with knee osteoarthritis. Clin. Rheumatol. 2010, Mar 28 [Epub ahead of print].
77. Gandhi R., Takahashi M., Syed K., Davey J.R., Mahomed N.N. Relationship between body habitus and joint leptin levels in a knee osteoarthritis population. J. Orthop. Res. 2010, 28:329-333.
78. Busso N., Karababa M., Nobile M., et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 2008, 3:e2267.